Prenatal Screening Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
All the vital news, analysis, and commentary curated by our industry experts.
Prenatal Screening Market Report Overview
The prenatal screening market size was valued at $642.3 million in 2022. In most countries, maternal serum screening and ultrasound remain standard-of-care for screening of pregnant women for chromosome aneuploidies and other birth defects. If these tests are positive, then prenatal diagnosis is typically performed via either amniocentesis or chorionic villus sampling (CVS). However, both amniocentesis and CVS are invasive techniques that have a risk of fetal death and miscarriage.
NIPT is performed using cell-free DNA from maternal blood, which is amplified and sequenced. Due to the sequencing process, NIPT is more expensive than maternal serum screening methods and this represents a major barrier in its widespread clinical adoption. In general, higher cost, low fetal fraction, and the occurrence of false positives are some of the challenging factors in the implementation of NIPT.
Prenatal Screening Market Outlook, 2022-2033 ($ Million)
For more insights into the prenatal screening market forecast, download a free report sample
The report is built to visualize quantitative market trends within in vitro diagnostics therapeutic area therapeutic areas. The model discusses in detail the impact of COVID-19 on the Prenatal screening market for the year 2020 and beyond. Each of the covered 39 country’s color-coded and fully sourced market models are equipped with epidemiology-based indications with procedure volumes.
|Market Size (2022)||$642.3 million|
|Key Regions||· North America
· Asia Pacific
· South Central America
· Middle East and Africa
|Key Segments||· Alpha-Fetoprotein (AFP) Tests
· Free Beta Human Chorionic Gonadotropin (hCG) Tests
· Inhibin A Tests
· Non-invasive prenatal testing (NIPT)
· Pregnancy Associated Plasma Protein A (PAPP-A) Tests
· Total Human Chorionic Gonadotropin (hCG) Tests
· Unconjugated Estriol (uE3) Tests
|Leading Companies||· Illumina Inc
· BGI Genomics Co Ltd
· Yourgene Health Plc
· Eurofins Scientific SE
· Agilent Technologies Inc
· Roche Diagnostics International Ltd
· PerkinElmer Inc
· Beckman Coulter Inc
· Abbott Laboratories
· Siemens Healthineers AG
· Quidel Corp
· Thermo Fisher Scientific Inc
· Tosoh Corp
|Enquire & Decide||Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.|
Prenatal Screening Market Dynamics
The incidence of Down Syndrome is increasing globally and awareness about disease and prenatal screening. Sales of Prenatal screening device depends upon disease incidence, live births rate, and number of pregnant women. Governments in many countries are taking initiatives to implement tests and offer fully funded prenatal screening to all pregnant women. The introduction of Non-Invasive Prenatal Testing (NIPT) has reduced the uptake of serum screening and invasive tests in many countries.
Prenatal Screening Market Segments
The prenatal screening market comprises key segments including Alpha-Fetoprotein (AFP) Tests, Free Beta Human Chorionic Gonadotropin (hCG) Tests, Inhibin A Tests, Non-invasive prenatal testing (NIPT), Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, and Unconjugated Estriol (uE3) Tests. In 2022, the Non-invasive prenatal testing (NIPT) segment dominated the prenatal screening market share.
Prenatal Screening Market Analysis by Segments, 2022 (%)
For more insights into the prenatal screening market segments, download a free report sample
Prenatal screening Market Segmentation by Regions
The key regions in the prenatal screening market are North America, Europe, Asia Pacific, South Central America, and the Middle East and Africa. North America has the largest share of the prenatal screening market. The number of prenatal screening is expected to grow in the forecast years throughout North America. This increase is mainly due to a growing preference for minimally invasive techniques.
The US and Canada both have large elderly populations, with approximately 40% of their total populations aged 50 years or older. These aging populations not only boost the size of the current arthroscopy shavers market but also provide strong potential for growth. In North America, there has been an increase in sports-related injuries due to the popularity of sports such as football, basketball, baseball, and ice hockey. In the US alone, there have been around 2.5 million sports-related injuries.
Prenatal screening Market Analysis by Regions, 2022 (%)
For more insights into the prenatal screening market segments, download a free report sample
Prenatal Screening Market - Competitive Landscape
Some of the leading companies in the prenatal screening market are Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, Roche Diagnostics International Ltd, PerkinElmer Inc, Beckman Coulter Inc, Abbott Laboratories, Siemens Healthineers AG, Quidel Corp, Thermo Fisher Scientific Inc, and Tosoh Corp among others. Illumina Inc held the largest share of the prenatal screening market in 2022.
Prenatal Screening Market Analysis by Companies, 2022 (%)
To know more about the leading companies in the prenatal screening market, download a free report sample
Segments Covered in the Report
Prenatal Screening Segments Outlook (Value, $ Million, 2015-2033)
- Alpha-Fetoprotein (AFP) Tests
- Free Beta Human Chorionic Gonadotropin (hCG) Tests
- Inhibin A Tests
- Non-invasive prenatal testing (NIPT)
- Pregnancy Associated Plasma Protein A (PAPP-A) Tests
- Total Human Chorionic Gonadotropin (hCG) Tests
- Unconjugated Estriol (uE3) Tests
Prenatal Screening Regional Outlook (Value, $ Million, 2015-2033)
- North America
- Asia Pacific
- South Central America
- Middle East and Africa
Key Inclusions of the market model are –
- Currently marketed Prenatal Screening and evolving competitive landscape –
- Insightful review of the key industry trends.
- Annualized total Prenatal Screening market revenue by segment and market outlooks from 2015-2033.
- Market level data on units, average selling prices and market values.
Global, Regional and Country level market specific insights –
- Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
- SWOT analysis for Prenatal Screening market.
- Competitive dynamics insights and trends provided for Prenatal Screening market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country specific overview of the healthcare system.
- Country specific reimbursement policies.
- Country specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, PerkinElmer Inc, Danaher Corp, Abbott Laboratories, Siemens AG, Quidelortho Corp, Thermo Fisher Scientific Inc, Tosoh Corp, Myriad Genetics Inc, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This report provides:
- Currently marketed prenatal screening and evolving competitive landscape.
- Insightful review of the key industry trends.
- Annualized total prenatal screening market revenue by segment and market outlooks.
- Granular data on total procedures, units, average selling prices, and market values by segment.
- Global, regional, and country-level market-specific insights.
- Qualitative market-specific information with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the prenatal screening market.
- Competitive dynamics insights and trends provided for the prenatal screening market.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific MedTech regulatory landscape.
Reasons to Buy
The model will enable you to –
- Understand the impact of COVID-19 on the prenatal screening market.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Prenatal screening market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the prenatal screening market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track device sales in the global and country-specific prenatal screening market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
BGI Genomics Co Ltd
Yourgene Health Plc
Eurofins Scientific SE
Agilent Technologies Inc
F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc
Myriad Genetics Inc
Frequently asked questions
What was the prenatal screening market size in 2022?
The prenatal screening market size was valued at $642.3 million in 2022.
Which region held the largest share of the prenatal screening market?
North America held the largest prenatal screening market share in 2022.
Which segment held the largest share of the prenatal screening market?
Non-invasive prenatal testing (NIPT) led the prenatal screening market in 2022.
Which are the major companies operating in the prenatal screening market?
Some of the leading companies in the prenatal screening market are Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, PerkinElmer Inc, Danaher Corp, Abbott Laboratories, Siemens AG, Quidelortho Corp, Thermo Fisher Scientific Inc, Tosoh Corp, Myriad Genetics Inc, and Others.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.